Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of June 2017, specifically reporting on a material definitive agreement entered into on June 19, 2017. The company is developing M-001, a product candidate intended as a primer for influenza vaccines.
Key Financial Metrics and Debt
The filing does not provide specific revenue, profit, cash flow, or margin data for the period. The primary financial disclosure relates to a new financing arrangement:
- Total Financing: Up to Euro 20 million from the European Investment Bank (EIB).
- Usage: Funding up to 50% of expected costs for developing and marketing M-001.
- Interest Rate: Interest-free during the term; penalty interest of EURIBOR + 2% applies only upon default.
- Repayment Terms: Single installment per tranche due five years after payment of that tranche.
- Revenue Share: EIB is entitled to 3% of annual M-001 sales revenues for ten years (or longer until a 2.8x cash-on-cash multiple is realized).
Material Changes and Tranche Structure
The financing is structured in three tranches contingent on specific milestones and evidence of matching funding:
- Tranche 1: Euro 4-6 million available within 12 months of the contract date.
- Tranche 2: Euro 4-6 million available within 24 months, subject to evidence of manufacturing the first clinical batch for Phase 3 trials.
- Tranche 3: Remaining amount to reach Euro 20 million total, available within 36 months, subject to authorization to launch Phase 3 trials.
The agreement includes a first-ranking floating charge over all company assets (excluding specific IP licensed from YEDA) as security.
Outlook, Risks, and Unusual Items
Prepayment Penalties: If the company prepays or if EIB demands prepayment due to events like a change of control or merger, the company must pay the principal plus the greater of: (i) an amount required for EIB to realize a 20% internal rate of return, or (ii) the principal amount.
Legal Jurisdiction: The contract is governed by the laws of England and Wales, with exclusive jurisdiction in English courts.
Risks: The funding is contingent on the company securing matching funds and achieving clinical milestones. Failure to meet these conditions may delay or prevent access to the full Euro 20 million.
Investor Verification Checklist
- Verify the company's ability to secure matching funding required to unlock each tranche.
- Confirm the timeline for manufacturing the first clinical batch for Phase 3 trials.
- Assess the impact of the 3% revenue royalty on future profitability of M-001.
- Review the specific assets excluded from the floating charge security agreement.
- Monitor for any change of control or senior management changes that could trigger prepayment penalties.